Peritoneal Effusion: An Uncommon Adverse Effects of Selective RET Inhibitors
Chylous effusion is a rare side effect observed during treatment with multikinase inhibitors (MKI) or selective RET tyrosine kinase inhibitors (TKIs) [1]. Pleura (12/22; 54%), peritoneum (5/22; 23%), or both (5/22; 23%) were common sites for chylous effusion. Selpercatinib (15/217; 7%) and MKIs (7/7371; <1%) were the most frequent causes. No confirmed effusion cases were observed with pralsetinib, but two RET rearranged NSCLC patients on pralsetinib had chylous ascites in a recent case series [2].